Evidence map›Paper›PMID 38421572›Full record

ArticleApplied biochemistry and biotechnology2024

Synthesis of Bimetallic Palladium/Zinc Oxide Nanocomposites Using Crocus sativus and Its Anticancer Activity via the Induction of Apoptosis in Cervical Cancer.

Jun Feng, Leilei He, Jin Qing Hui, Krishnamoorthy Kavithaa, Zhengzheng Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Jun Feng *Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou Jiangsu, 215000, China.
Leilei He *Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, 221000, Jiangsu, China.
Jin Qing HuiDepartment of Surgical, Shaanxi Kangfu Hospital, Xian, 710065, Shaanxi, China.
Krishnamoorthy KavithaaDepartment of Biotechnology, Hindusthan College Arts and Science, Coimbatore, TN, India.
Zhengzheng XuDepartment of Gynaecology, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, 430000, Hubei, China. xuzhengzheng818@sina.com.
Hindustan Institute of Technology and Science · INIntegrated Chinese Medicine (China) · CNShaanxi Provincial People's Hospital · CNThe Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)Xuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palladium (Pd) and zinc oxide (ZnO) (Pd/ZnO NPs) bimettalic nanocomposites still lag much too far behind other nanoparticles investigated for various biological uses in the area of cancer treatments. Chemically created nanoparticles agglomerate under physiological conditions, impeding their use in biomedical applications. In this study, a straightforward and environmentally friendly method for creating bimetallic nanoparticles (NPs) by combining palladium (Pd) and zinc oxide (ZnO) using Crocus sativus extract (CS-Pd/ZnO NCs) was reported; the bio-synthesize bimetallic palladium/zinc oxide nanocomposites and their antioxidant and anti-cancer properties were assessed. The developed Pd/ZnO NPs were characterized using different approaches, including UV-vis, DLS, FTIR, EDX, and SEM analyses. The present investigation shows how nanocomposites are made, their distinctive properties, antioxidant activity, anticancer mechanisms, and their potential therapeutic applications. DPPH and ABTS tests were used to investigate antioxidant activity. Further, the effects of CS-Pd/ZnO NCs on HeLa cells were assessed using the cell viability, ROS generation, MMP levels, and induced apoptosis. Apoptosis induction was measured using an Annexin V-fluorescein isothicyanate assay. Cell DNA was stained with propidium iodide to evaluate the impact upon this cell cycle. Time-dependent cell death was carried on by CS-Pd/ZnO NCs. The maximum inhibitory effect was 59 ± 3.2 when dosages of 4.5 µg/mL or higher were delivered after 24 h of treatment. Additionally, the CS-Pd/ZnO NCs caused HeLa cells to undergo apoptosis. Apoptotic HeLa cells were present in 35.64% of the treated cells at 4.5 µg/mL, and the cell cycle arrest at G0/G1 phase occurred concurrently. According to these findings, the CS-Pd/ZnO NCs may be a promising candidate for the creation of brand-new cervical cancer treatment.

Indexed as

Antineoplastic AgentsApoptosisCrocusNanocompositesPalladiumUterine Cervical NeoplasmsZinc OxideAntioxidantsCell SurvivalFemaleHeLa CellsHumansMetal NanoparticlesPlant ExtractsReactive Oxygen SpeciesAntineoplastic AgentsAntioxidantsPalladiumPlant ExtractsReactive Oxygen SpeciesZinc OxideAntioxidantCervical cancerCrocus sativusPalladiumZinc oxide

Identifiers

PMID38421572
OpenAlexW4392298516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.